Skip to main content
Erschienen in: Endocrine 2/2012

01.10.2012 | Original Article

Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women

verfasst von: Seong-Su Moon, Young-Sil Lee, Sung Woo Kim

Erschienen in: Endocrine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis is a disease associated with insulin resistant states such as central obesity, diabetes, and metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD) is also increased in such conditions. However, little is known about whether osteoporosis and nonalcoholic fatty liver disease are etiologically related to each other or not. We examined whether bone mineral density (BMD) is associated with NAFLD in pre- and postmenopausal women. Four hundred eighty-one female subjects (216 premenopausal and 265 postmenopausal) were enrolled. Lumbar BMD was measured using dual-energy X-ray absorptiometry. Liver ultrasonography was done to check the severity of fatty liver. We excluded subjects with a secondary cause of liver disease. Blood pressure, lipid profile, fasting plasma glucose, alanine aminotransferase (ALT), aspartate aminotransferase, and body mass index were measured in every subject. Mean lumbar BMD was lower in subjects with NAFLD than those without NAFLD in postmenopausal women (0.98 ± 0.01 vs. 1.01 ± 0.02 g/cm2, P = 0.046). Multiple correlation analysis revealed a significant association between mean lumbar BMD and NAFLD in postmenopausal subjects after adjusting for age, body mass index, ALT, smoking status, and alcohol consumption (β coefficient −0.066, 95% CI −0.105 to −0.027, P = 0.001). Even after adjusting the presence of metabolic syndrome, the significance was maintained (β coefficient −0.043, 95% CI −0.082 to −0.004, P = 0.031). Lumbar BMD is related with NAFLD in postmenopausal females. We suggest that postmenopausal women with NAFLD may have a higher risk of osteoporosis than those without.
Literatur
1.
Zurück zum Zitat Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94(6), 646–650 (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94(6), 646–650 (1993)
2.
Zurück zum Zitat C. Cooper, E.J. Atkinson, S.J. Jacobsen, W.M. O’Fallon, L.J. Melton 3rd, Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 137(9), 1001–1005 (1993)PubMed C. Cooper, E.J. Atkinson, S.J. Jacobsen, W.M. O’Fallon, L.J. Melton 3rd, Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 137(9), 1001–1005 (1993)PubMed
3.
Zurück zum Zitat M.A. Petit, M.L. Paudel, B.C. Taylor, J.M. Hughes, E.S. Strotmeyer, A.V. Schwartz, J.A. Cauley, J.M. Zmuda, A.R. Hoffman, K.E. Ensrud, Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J. Bone Miner. Res. 25(2), 285–291 (2010) M.A. Petit, M.L. Paudel, B.C. Taylor, J.M. Hughes, E.S. Strotmeyer, A.V. Schwartz, J.A. Cauley, J.M. Zmuda, A.R. Hoffman, K.E. Ensrud, Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J. Bone Miner. Res. 25(2), 285–291 (2010)
4.
Zurück zum Zitat D. von Muhlen, S. Safii, S.K. Jassal, J. Svartberg, E. Barrett-Connor, Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos. Int. 18(10), 1337–1344 (2007)CrossRef D. von Muhlen, S. Safii, S.K. Jassal, J. Svartberg, E. Barrett-Connor, Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos. Int. 18(10), 1337–1344 (2007)CrossRef
5.
Zurück zum Zitat D.K. Hwang, H.J. Choi, The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos. Int. 21(3), 425–431 (2010) D.K. Hwang, H.J. Choi, The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos. Int. 21(3), 425–431 (2010)
6.
Zurück zum Zitat Kim, K.C., Shin, D.H., Lee, S.Y., Im, J.A., Lee, D.C.: Relation between obesity and bone mineral density and vertebral fractures in Korean postmenopausal women. Yonsei Med J 51(6), 857–863 (2010) Kim, K.C., Shin, D.H., Lee, S.Y., Im, J.A., Lee, D.C.: Relation between obesity and bone mineral density and vertebral fractures in Korean postmenopausal women. Yonsei Med J 51(6), 857–863 (2010)
7.
Zurück zum Zitat Y.K. Jeon, J.G. Lee, S.S. Kim, B.H. Kim, S.J. Kim, Y.K. Kim, I.J. Kim, Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocr. J. 58(2), 87–93 (2011) Y.K. Jeon, J.G. Lee, S.S. Kim, B.H. Kim, S.J. Kim, Y.K. Kim, I.J. Kim, Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocr. J. 58(2), 87–93 (2011)
8.
Zurück zum Zitat M.A. Cornier, D. Dabelea, T.L. Hernandez, R.C. Lindstrom, A.J. Steig, N.R. Stob, R.E. Van Pelt, H. Wang, R.H. Eckel, The metabolic syndrome. Endocr. Rev. 29(7), 777–822 (2008)PubMedCrossRef M.A. Cornier, D. Dabelea, T.L. Hernandez, R.C. Lindstrom, A.J. Steig, N.R. Stob, R.E. Van Pelt, H. Wang, R.H. Eckel, The metabolic syndrome. Endocr. Rev. 29(7), 777–822 (2008)PubMedCrossRef
9.
Zurück zum Zitat G.A. Bray, T. Bellanger, Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29(1), 109–117 (2006)PubMedCrossRef G.A. Bray, T. Bellanger, Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29(1), 109–117 (2006)PubMedCrossRef
10.
Zurück zum Zitat Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002)
11.
Zurück zum Zitat A.I. Shulman, D.J. Mangelsdorf, Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 353(6), 604–615 (2005)PubMedCrossRef A.I. Shulman, D.J. Mangelsdorf, Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 353(6), 604–615 (2005)PubMedCrossRef
12.
Zurück zum Zitat E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40(3), 332–343 (2011) E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40(3), 332–343 (2011)
13.
14.
Zurück zum Zitat G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, C. Day, G. Arcaro, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30(5), 1212–1218 (2007)PubMedCrossRef G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, C. Day, G. Arcaro, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30(5), 1212–1218 (2007)PubMedCrossRef
15.
Zurück zum Zitat S. Bellentani, G. Saccoccio, F. Masutti, L.S. Croce, G. Brandi, F. Sasso, G. Cristanini, C. Tiribelli, Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132(2), 112–117 (2000)PubMed S. Bellentani, G. Saccoccio, F. Masutti, L.S. Croce, G. Brandi, F. Sasso, G. Cristanini, C. Tiribelli, Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132(2), 112–117 (2000)PubMed
16.
Zurück zum Zitat J.R. Lewis, S.R. Mohanty, Nonalcoholic fatty liver disease: a review and update. Dig. Dis. Sci. 55(3), 560–578 (2010) J.R. Lewis, S.R. Mohanty, Nonalcoholic fatty liver disease: a review and update. Dig. Dis. Sci. 55(3), 560–578 (2010)
17.
Zurück zum Zitat M. Lazo, J.M. Clark, The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 28(4), 339–350 (2008)PubMedCrossRef M. Lazo, J.M. Clark, The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 28(4), 339–350 (2008)PubMedCrossRef
18.
Zurück zum Zitat C. Loguercio, T. De Simone, M.V. D’Auria, I. de Sio, A. Federico, C. Tuccillo, A.M. Abbatecola, C. Del Vecchio Blanco, Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig. Liver Dis. 36(6), 398–405 (2004). doi:10.1016/j.dld.2004.01.022 C. Loguercio, T. De Simone, M.V. D’Auria, I. de Sio, A. Federico, C. Tuccillo, A.M. Abbatecola, C. Del Vecchio Blanco, Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig. Liver Dis. 36(6), 398–405 (2004). doi:10.​1016/​j.​dld.​2004.​01.​022
19.
Zurück zum Zitat C. Loguercio, V. De Girolamo, I. de Sio, C. Tuccillo, A. Ascione, F. Baldi, G. Budillon, L. Cimino, A. Di Carlo, M.P. Di Marino, F. Morisco, F. Picciotto, L. Terracciano, R. Vecchione, V. Verde, C. Del Vecchio Blanco, Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J. Hepatol. 35(5), 568–574 (2001)PubMedCrossRef C. Loguercio, V. De Girolamo, I. de Sio, C. Tuccillo, A. Ascione, F. Baldi, G. Budillon, L. Cimino, A. Di Carlo, M.P. Di Marino, F. Morisco, F. Picciotto, L. Terracciano, R. Vecchione, V. Verde, C. Del Vecchio Blanco, Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J. Hepatol. 35(5), 568–574 (2001)PubMedCrossRef
20.
Zurück zum Zitat World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communication, Sydney (2000) World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communication, Sydney (2000)
21.
Zurück zum Zitat A.J. Sanyal, AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123(5), 1705–1725 (2002)PubMedCrossRef A.J. Sanyal, AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123(5), 1705–1725 (2002)PubMedCrossRef
22.
Zurück zum Zitat D. Joy, V.R. Thava, B.B. Scott, Diagnosis of fatty liver disease: Is biopsy necessary? Eur. J. Gastroenterol. Hepatol. 15(5), 539–543 (2003)PubMed D. Joy, V.R. Thava, B.B. Scott, Diagnosis of fatty liver disease: Is biopsy necessary? Eur. J. Gastroenterol. Hepatol. 15(5), 539–543 (2003)PubMed
23.
Zurück zum Zitat S.H. Park, W.K. Jeon, S.H. Kim, H.J. Kim, D.I. Park, Y.K. Cho, I.K. Sung, C.I. Sohn, D.K. Keum, B.I. Kim, Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 21(1 Pt 1), 138–143 (2006)PubMedCrossRef S.H. Park, W.K. Jeon, S.H. Kim, H.J. Kim, D.I. Park, Y.K. Cho, I.K. Sung, C.I. Sohn, D.K. Keum, B.I. Kim, Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 21(1 Pt 1), 138–143 (2006)PubMedCrossRef
24.
Zurück zum Zitat J.M. Clark, F.L. Brancati, A.M. Diehl, Nonalcoholic fatty liver disease. Gastroenterology 122(6), 1649–1657 (2002)PubMedCrossRef J.M. Clark, F.L. Brancati, A.M. Diehl, Nonalcoholic fatty liver disease. Gastroenterology 122(6), 1649–1657 (2002)PubMedCrossRef
25.
Zurück zum Zitat A. Suzuki, M.F. Abdelmalek, Nonalcoholic fatty liver disease in women. Womens Health (Lond. Engl.) 5(2), 191–203 (2009)CrossRef A. Suzuki, M.F. Abdelmalek, Nonalcoholic fatty liver disease in women. Womens Health (Lond. Engl.) 5(2), 191–203 (2009)CrossRef
26.
Zurück zum Zitat Y.H. Hsu, S.A. Venners, H.A. Terwedow, Y. Feng, T. Niu, Z. Li, N. Laird, J.D. Brain, S.R. Cummings, M.L. Bouxsein, C.J. Rosen, X. Xu, Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am. J. Clin. Nutr. 83(1), 146–154 (2006) Y.H. Hsu, S.A. Venners, H.A. Terwedow, Y. Feng, T. Niu, Z. Li, N. Laird, J.D. Brain, S.R. Cummings, M.L. Bouxsein, C.J. Rosen, X. Xu, Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am. J. Clin. Nutr. 83(1), 146–154 (2006)
27.
Zurück zum Zitat L.J. Zhao, Y.J. Liu, P.Y. Liu, J. Hamilton, R.R. Recker, H.W. Deng, Relationship of obesity with osteoporosis. J. Clin. Endocrinol. Metab. 92(5), 1640–1646 (2007). doi:10.1210/jc.2006-0572 L.J. Zhao, Y.J. Liu, P.Y. Liu, J. Hamilton, R.R. Recker, H.W. Deng, Relationship of obesity with osteoporosis. J. Clin. Endocrinol. Metab. 92(5), 1640–1646 (2007). doi:10.​1210/​jc.​2006-0572
28.
Zurück zum Zitat W.Y. Lee, J.S. Park, S.Y. Noh, E.J. Rhee, K.C. Sung, B.S. Kim, J.H. Kang, S.W. Kim, M.H. Lee, J.R. Park, C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int. J. Cardiol. 97(1), 101–106 (2004)PubMedCrossRef W.Y. Lee, J.S. Park, S.Y. Noh, E.J. Rhee, K.C. Sung, B.S. Kim, J.H. Kang, S.W. Kim, M.H. Lee, J.R. Park, C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int. J. Cardiol. 97(1), 101–106 (2004)PubMedCrossRef
29.
Zurück zum Zitat D.H. Jones, Y.Y. Kong, J.M. Penninger, Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. 61(Suppl 2), ii32–39 (2002) D.H. Jones, Y.Y. Kong, J.M. Penninger, Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. 61(Suppl 2), ii32–39 (2002)
30.
Zurück zum Zitat L.C. Hofbauer, M. Schoppet, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292(4), 490–495 (2004)PubMedCrossRef L.C. Hofbauer, M. Schoppet, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292(4), 490–495 (2004)PubMedCrossRef
31.
Zurück zum Zitat M. Krawczyk, L. Bonfrate, P. Portincasa, Nonalcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 24(5), 695–708 (2010) M. Krawczyk, L. Bonfrate, P. Portincasa, Nonalcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 24(5), 695–708 (2010)
32.
Zurück zum Zitat P. Trayhurn, I.S. Wood, Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 33(Pt 5), 1078–1081 (2005)PubMed P. Trayhurn, I.S. Wood, Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 33(Pt 5), 1078–1081 (2005)PubMed
33.
Zurück zum Zitat P. Trayhurn, Adipose tissue in obesity—an inflammatory issue. Endocrinology 146(3), 1003–1005 (2005)PubMedCrossRef P. Trayhurn, Adipose tissue in obesity—an inflammatory issue. Endocrinology 146(3), 1003–1005 (2005)PubMedCrossRef
34.
Zurück zum Zitat T. Diamond, D. Stiel, M. Lunzer, M. Wilkinson, J. Roche, S. Posen, Osteoporosis and skeletal fractures in chronic liver disease. Gut 31(1), 82–87 (1990)PubMedCrossRef T. Diamond, D. Stiel, M. Lunzer, M. Wilkinson, J. Roche, S. Posen, Osteoporosis and skeletal fractures in chronic liver disease. Gut 31(1), 82–87 (1990)PubMedCrossRef
35.
Zurück zum Zitat P. Angulo, T.M. Therneau, A. Jorgensen, C.K. DeSotel, K.S. Egan, E.R. Dickson, J.E. Hay, K.D. Lindor, Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J. Hepatol. 29(5), 729–735 (1998)PubMedCrossRef P. Angulo, T.M. Therneau, A. Jorgensen, C.K. DeSotel, K.S. Egan, E.R. Dickson, J.E. Hay, K.D. Lindor, Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J. Hepatol. 29(5), 729–735 (1998)PubMedCrossRef
36.
Zurück zum Zitat S.P. Pereira, G.P. Bray, P.I. Pitt, F. Li, C. Moniz, R. Williams, Non-invasive assessment of bone density in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11(3), 323–328 (1999)PubMedCrossRef S.P. Pereira, G.P. Bray, P.I. Pitt, F. Li, C. Moniz, R. Williams, Non-invasive assessment of bone density in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11(3), 323–328 (1999)PubMedCrossRef
37.
Zurück zum Zitat J. Newton, R. Francis, M. Prince, O. James, M. Bassendine, D. Rawlings, D. Jones, Osteoporosis in primary biliary cirrhosis revisited. Gut 49(2), 282–287 (2001)PubMedCrossRef J. Newton, R. Francis, M. Prince, O. James, M. Bassendine, D. Rawlings, D. Jones, Osteoporosis in primary biliary cirrhosis revisited. Gut 49(2), 282–287 (2001)PubMedCrossRef
38.
Zurück zum Zitat G.W. McCaughan, R.B. Feller, Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig. Dis. 12(4), 223–231 (1994)PubMedCrossRef G.W. McCaughan, R.B. Feller, Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig. Dis. 12(4), 223–231 (1994)PubMedCrossRef
39.
Zurück zum Zitat C.H. Janes, E.R. Dickson, R. Okazaki, S. Bonde, A.F. McDonagh, B.L. Riggs, Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95(6), 2581–2586 (1995)PubMedCrossRef C.H. Janes, E.R. Dickson, R. Okazaki, S. Bonde, A.F. McDonagh, B.L. Riggs, Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95(6), 2581–2586 (1995)PubMedCrossRef
40.
Zurück zum Zitat F.J. Gallego-Rojo, J.L. Gonzalez-Calvin, M. Munoz-Torres, J.L. Mundi, R. Fernandez-Perez, D. Rodrigo-Moreno, Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28(3), 695–699 (1998)PubMedCrossRef F.J. Gallego-Rojo, J.L. Gonzalez-Calvin, M. Munoz-Torres, J.L. Mundi, R. Fernandez-Perez, D. Rodrigo-Moreno, Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28(3), 695–699 (1998)PubMedCrossRef
41.
Zurück zum Zitat J.A. Cuthbert, C.Y. Pak, J.E. Zerwekh, K.D. Glass, B. Combes, Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 4(1), 1–8 (1984)PubMedCrossRef J.A. Cuthbert, C.Y. Pak, J.E. Zerwekh, K.D. Glass, B. Combes, Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 4(1), 1–8 (1984)PubMedCrossRef
42.
Zurück zum Zitat G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40(1), 102–108 (2011) G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40(1), 102–108 (2011)
43.
Zurück zum Zitat G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012) G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012)
Metadaten
Titel
Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women
verfasst von
Seong-Su Moon
Young-Sil Lee
Sung Woo Kim
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9639-6

Weitere Artikel der Ausgabe 2/2012

Endocrine 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.